UAE – Novartis and the Emirates Oncology Society (EOS) have joined forces to launch a new healthcare initiative to support better access to breast cancer care in the United Arab Emirates.
Novartis uses innovative science and digital technologies to create transformative treatments in areas of great medical need. The company is reimagining medicine to improve and extend people’s lives.
In a press statement, Mohamed Ezz Eldin, Head of Gulf Countries at Novartis, said: “Through the new partnership, we aim to not only provide innovative treatment solutions but also foster a deeper understanding of the disease’s complexities in the Gulf region.”
He underscored that breast cancer care is one area where significant advancements are possible while reiterating the company’s vision to leave no patient behind and to drive progress in breast cancer care.
Under the new deal, Novartis and the Emirates Oncology Society have introduced a new initiative titled United for Breast Cancer – A Commitment for Excellence and Innovation.
The new initiative, United for Breast Cancer – A Commitment for Excellence and Innovation, aims to address these pressing challenges through three key pillars.
In his adress, Professor Humaid Al-Shamsi, President of The Emirates Oncology Society, said: “This partnership marks a significant step forward in our commitment to transforming breast cancer care in the UAE and beyond.”
Professor Humaid Al-Shamsi expressed his belief that this collaboration will lead to a brighter future for all patients affected by breast cancer.
The main purpose of the first pillar of this new initiative is to increase awareness of breast cancer and early diagnosis of people with breast cancer symptoms.
Related to this, the focus will be placed on empowering patients to go for regular screenings, enhance communication with healthcare providers, and expand their understanding of the disease.
“By working together with Novartis, we aim to empower patients with knowledge, enhance healthcare providers’ capabilities, and create a robust foundation of data to guide our efforts,” outlined Humaid Al Shamsi.
Secondly, the strategic partnership between Emirates Oncology Society and Novartis will help in providing scientific educational platforms for healthcare providers.
This pillar will focus on defining standards of care and treatment goals, disseminating the latest advancements in the treatment landscape, and encouraging the adoption of innovative treatment solutions.
Equally important, the third pillar emphasizes the importance of research and data in understanding and addressing breast cancer.
In his address, Joy Khoury, Head of Communications and Patient Engagement for the Gulf Cooperation Council (GCC) at Novartis, emphasized the importance of raising awareness and supporting patients in improving breast cancer outcomes.
“This partnership is a welcome step forward in our efforts to create a more informed and supported patient community and empower patients with knowledge that will make a difference in their lives,” stated Joy Khoury.
As the world marks the end of Breast Cancer Awareness Month, the launch of the new initiative was held at Raffles Hotel in the Emirate of Dubai, where the parties signed a letter of pioneering partnership committing to working together until October 2024.
The pioneering partnership aims to transform the landscape of breast cancer care in the UAE and generate local data to enhance the treatment and care of breast cancer patients across the Emirates.
It is a shared vision that both companies actively strive to improve early diagnosis of breast cancer, treatment outcomes, and the overall patient experience.
This partnership is about providing healthcare providers with the latest tools and advancing research to fill critical data gaps to make tangible improvements in the breast cancer care landscape across the UAE.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
